SCHEMBL4095231

SCHEMBL4095231

Clc1ccc(-c2nc(N3CCCC3)c3cc(Cl)ccc3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.58
KDM4E B2RXH2 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
STAT6 P42226 1/20 0.54
TSHR P16473 2/20 0.53
MEN1 O00255 1/20 0.53
USP2 O75604 1/20 0.53
KMT2A Q03164 1/20 0.53
ABCG2 Q9UNQ0 2/20 0.53
MAPT P10636 3/20 0.52
LMNA P02545 1/20 0.52
GBA1 P04062 2/20 0.52
ADORA3 P0DMS8 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA1 P30542 1/20 0.51
FABP3 P05413 2/20 0.50
FABP4 P15090 2/20 0.50
FABP5 Q01469 2/20 0.50
ABCB1 P08183 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092114 0.89 MEN1 (0.57) ACP1KDM4ENPSR1STAT6TSHR
SCHEMBL4095097 0.88 HDAC3 (0.62) KDM4ENPSR1TSHRMEN1USP2
SCHEMBL4091890 0.88 NPSR1 (0.57) ACP1KDM4ENPSR1STAT6ABCG2
SCHEMBL1084186 0.86 ACP1 (0.81) ACP1NPSR1TSHRMEN1USP2
SCHEMBL4085035 0.84 ACP1 (0.81) ACP1NPSR1TSHRMEN1USP2
SCHEMBL4085088 0.83 EGLN1 (0.49) ACP1KDM4ENPSR1STAT6TSHR
SCHEMBL4084671 0.82 HDAC3 (0.54) NPSR1TSHRUSP2ABCG2MAPT
SCHEMBL4755939 0.81 ABCG2 (0.50) ACP1KDM4ETSHRUSP2ABCG2
SCHEMBL4091151 0.81 ABCB1 (0.76) ACP1KDM4ENPSR1STAT6TSHR
SCHEMBL7262669 0.81 KDM4E (0.76) ACP1KDM4ENPSR1STAT6ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ACP1 3504/4885KDM4E 1626/4885NPSR1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.